Ibn Sina Pharmaceutical reported a strong profit surge in its latest quarter, with net earnings more than doubling, a boost that could lift investor confidence and support the company’s next growth steps. The firm said net profit rose sharply to Tk 22 crore on the back of higher sales and some extra income, while total revenue climbed about 35 percent to Tk 372 crore and other income increased to roughly Tk 94 lakh, clear signs that demand for its medicines and related products is improving across markets. Earnings per share also rose strongly, jumping to Tk 7.08 from Tk 2.72, giving shareholders a clearer picture of improved returns. At the same time, the company noted a fall in net operating cash flow per share to Tk 5.46 from Tk 9.71, a reminder that healthy profit growth needs to be matched by steady cash management so day-to-day operations and supplier payments stay smooth. Company leaders said the gains came from stronger sales, careful cost control and higher other income that helped offset rising selling and administrative expenses, and they are planning to use the improved results to keep investing in reliable supply, better production and product quality. Observers said the firm’s consolidated performance reflects not just one part of the business but the wider group, including its natural medicine and manufacturing arms, which together help market well over a hundred products to hospitals, clinics and retail outlets. Industry contacts noted that when a pharmaceutical company posts both rising revenue and higher profit, it can unlock funds for product upgrades, better packaging and expanded distribution, all of which help doctors and patients get safer, more available medicines. For investors and small partners, the figures signal strength but also point to tasks ahead: the company needs to convert profits into steady cash and keep close watch on expenses, inventory and credit so growth is long lasting. Analysts say steady marketing, sound pricing and reliable quality checks will be key for the firm to keep winning orders from hospitals and pharmacies while building trust with buyers. The company’s move to balance growth with practical steps on cash flow and cost control could also create more local jobs in production and logistics and support suppliers in the value chain. Overall, the report offers a positive picture: higher sales, sharply better profit and stronger earnings per share that together give the firm a firmer base to invest in better products, wider reach and continued service to the health sector, while it keeps an eye on cash flow and operational needs to make sure gains are durable and helpful to customers, workers and investors alike. Management says it will share practical updates as progress continues with stakeholders.
